Zealand Pharma A/S – American Depositary Shares (ZEAL) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research downgraded shares of Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL) from a buy rating to a hold rating in a research note issued to investors on Saturday.

According to Zacks, “Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark. “

Several other research analysts also recently commented on the company. Needham & Company LLC reissued a buy rating and issued a $26.00 target price on shares of Zealand Pharma A/S – American Depositary Shares in a report on Monday, October 16th. Goldman Sachs Group started coverage on Zealand Pharma A/S – American Depositary Shares in a report on Wednesday, September 27th. They issued a buy rating on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Zealand Pharma A/S – American Depositary Shares currently has a consensus rating of Buy and an average price target of $24.75.

Shares of Zealand Pharma A/S – American Depositary Shares (ZEAL) traded up $0.26 on Friday, hitting $15.13. The stock had a trading volume of 8,800 shares, compared to its average volume of 11,610. Zealand Pharma A/S – American Depositary Shares has a fifty-two week low of $12.45 and a fifty-two week high of $20.37.

Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL) last announced its earnings results on Wednesday, November 8th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.13. research analysts anticipate that Zealand Pharma A/S – American Depositary Shares will post -1.46 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC bought a new position in Zealand Pharma A/S – American Depositary Shares in the 3rd quarter worth approximately $386,000. Royce & Associates LP acquired a new position in shares of Zealand Pharma A/S – American Depositary Shares in the 3rd quarter valued at $1,152,000. Finally, Susquehanna International Group LLP acquired a new position in shares of Zealand Pharma A/S – American Depositary Shares in the 3rd quarter valued at $3,185,000. Hedge funds and other institutional investors own 13.33% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3142629/zealand-pharma-as-american-depositary-shares-zeal-stock-rating-lowered-by-zacks-investment-research.html.

About Zealand Pharma A/S – American Depositary Shares

Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes.

Get a free copy of the Zacks research report on Zealand Pharma A/S – American Depositary Shares (ZEAL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zealand Pharma A/S - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.